Massachusetts is currently home to 3215 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892
Recruiting
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are f... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
Register for Updates
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
NCT06088979
Recruiting
Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/12/2025
Locations: Ophthalmic Consultants of Boston Site - 0128, Boston, Massachusetts
Conditions: Thyroid Eye Disease
Register for Updates
PrEP and MOUD Rapid Access for Persons Who Inject Drugs: The CHORUS+ Study
NCT05769218
Recruiting
The US opioid overdose epidemic has been accompanied by an increase in human immunodeficiency (HIV) among persons who inject drugs. HIV pre-exposure prophylaxis (PrEP) is an FDA approved medication taken daily orally by individuals who are HIV negative, but who are at increased risk for HIV. In order to obtain PrEP, a prescription is needed. Before being prescribed HIV PrEP, it is recommended by the Centers for Disease Control and Prevention (CDC) to obtain an HIV test first. Although home HIV s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Boston Medical Center Faster Paths Bridge Clinic, Boston, Massachusetts
Conditions: Opioid Use Disorder
Register for Updates
Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System
NCT04798261
Recruiting
The objective of this study is to evaluate real world long-term functional outcomes, safety and performance of the Indigo Aspiration System for the treatment of pulmonary embolism (PE).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Pulmonary Embolism
Register for Updates
Intraoperative Tumor Margin Identification With ICG Dye Imaging
NCT04752137
Recruiting
In this research study we want to learn more about the use of indocyanine green (ICG) during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that is used in medical diagnostics. We want to determine if ICG-guided tumor resection is more effective in obtaining negative margins. Lastly, we want to assess traditional oncologic outcomes of local recurrence, time to metastatic disease, and overall and disease specific survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Benign Neoplasm, Malignant Neoplasm
Register for Updates
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
NCT04580420
Recruiting
The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.
Gender:
ALL
Ages:
All
Trial Updated:
05/12/2025
Locations: Clinical Trial Site, Boston, Massachusetts
Conditions: End Stage Renal Disease, Primary Hyperoxaluria Type 1
Register for Updates
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
NCT04227847
Recruiting
This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for participants with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study SEA-CD70 to find out what its side effects are and if it works for AML and MDS. A side effect is anything the drug does besides treating cancer. This study will have seven groups or "parts." * Part A will find out how much SEA-CD70 should be given to participants * Part B will use the dose fou... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Register for Updates
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776
Recruiting
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
Register for Updates
LET Optimized IMPT in Treating Pediatric Patients With Ependymoma
NCT03750513
Recruiting
This phase I trial studies the side effects of linear energy transfer (LET) optimized image modulated proton therapy (IMPT) in treating pediatric patients with ependymoma. Radiation therapy such as LET optimized IMPT, uses proton beams to kill tumor cells and shrink tumors without damaging surrounding normal tissues.
Gender:
ALL
Ages:
22 years and below
Trial Updated:
05/12/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Anaplastic Ependymoma, Ependymoma
Register for Updates
Stroke Motor Rehabilitation and Recovery Study
NCT03485040
Recruiting
SMaHRT (Stroke Motor reHabiliation and Recovery sTudy) is a longitudinal study aimed at understanding the natural history of upper extremity motor recovery after ischemic and hemorrhagic stroke.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/12/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Stroke, Ischemic
Register for Updates
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
NCT03418961
Recruiting
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Lahey Hospital and Medical Center, Burlington, Massachusetts
Conditions: Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Register for Updates
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
NCT06433947
Recruiting
Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/11/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates